News

  • 27 August 2018

    Genkyotex (Paris:GKTX) (Brussels:GKTX) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that 90 patients have been randomized in its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC). This represents the target number of patients required to conduct the pre-planned interim analysis. The analysis will be conducted when these patients have completed 6 weeks of dosing.

  • 20 August 2018

    Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, today announces that it has dosed the first patient in a Phase I study, part of an ongoing collaboration with GlaxoSmithKline (GSK).

  • 15 August 2018

    Sonendo®, Inc., the developer of breakthrough technology for the dental marketplace, today announced that their GentleWave® System is now designed to integrate with TDO® endodontic software. TDO®Software is the only Practice Management Software that integrates with the GentleWave® System. This integration will allow endodontists who use the TDO endodontic software, affectionately known as TDO’ers, to more efficiently record, and retrieve, important procedure information directly from the GentleWave System’s console; the result is an improvement in chairside treatment efficiency.

  • 9 August 2018

    InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019 instead of in the fourth quarter of 2018 as previously communicated.

  • 3 August 2018

    JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment in the Early Feasibility Study (EFS) of its next generation JenaValve Pericardial TAVR System using the Everdur™ transcatheter heart valve (THV) and CoronatixTM Transfemoral Delivery Catheter at NewYork-Presbyterian/ Columbia University Medical Center (CUMC), New York City, and MedStar Washington Hospital Center, Washington, DC. The EFS is investigating the JenaValve Pericardial TAVR System for the minimally invasive treatment of patients with symptomatic, severe aortic stenosis (AS) and symptomatic, severe aortic regurgitation (AR) for whom open surgery is an extreme or high risk. The JenaValve Pericardial TAVR System is an investigational device in the United States and internationally.